1alpha-Hydroxy VD4

• CAT Number: I001653
• CAS Number: 143032-85-3
• Molecular Formula: C28H46O2
• Molecular Weight: 414.66
• Purity: 97%
• Synonyms: (Z)-5-((E)-2-(1-(5,6-dimethylheptan-2-yl)-7a-methylhexahydro-1H-inden-4(2H)-ylidene)ethylidene)-4-methylenecyclohexane-1,3-diol
• Target: VD/VDR
• Solubility: 10 mM in DMSO
• Storage: Store at -20°C
• Analysis method: HPLC
• IUPAC Name: (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(2R,5S)-5,6-dimethylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-dio
• InChI: InChI=1S/C28H46O2/c1-18(2)19(3)9-10-20(4)25-13-14-26-22(8-7-15-28(25,26)6)11-12-23-16-24(29)17-27(30)21(23)5/h11-12,18-20,24-27,29-30H,5,7-10,13-17H2,1-4,6H3/b22-11+,23-12-/t19-,20+,24+,25+,26-,27-,28+/m0/s1
• InChIKey: NEETXMRNUNEBRH-GOTXBORWSA-N
• SMILES: C[C@H](CC[C@H](C)C(C)C)[C@H]1CC[C@@H]2[C@@]1(CCC/C2=CC=C/3C[C@H](C[C@@H](C3=C)O)O)C

1alpha-Hydroxy VD4 (Cat.No: I001653), also known as alfacalcidol, is a synthetic vitamin D analog that is used in the treatment of various bone disorders, including osteoporosis and renal osteodystrophy. It is a prodrug that is converted in the liver to the active form of vitamin D, calcitriol. 1alpha-Hydroxy VD4 has been shown to increase calcium absorption and bone mineral density, while also reducing the risk of fractures.

Reference

[1]. M Makishima, et al. Growth inhibition and differentiation induction in human monoblastic leukaemia cells by 1alpha-hydroxyvitamin D derivatives and their enhancement by combination with hydroxyurea. British Journal of Cancer (1998) 77, 33-39 Abstract The active form of vitamin D, 1α,25-dihydroxyvitamin D3 (1,25(OH)2D3), is a potent inducer of differentiation in myeloid leukemia cells, but its clin. use is limited because of its hypercalcemic activity. The authors examd. the ability of 1,25(OH)2D3 in combination with several anti-cancer drugs to inhibit the proliferation of, and induce differentiation in, human monoblastic leukemia U937 cells. Hydroxyurea (HU), cytarabine and camptothecin showed effective synergism with 1,25(OH)2D3 with regard to growth inhibition, while daunorubicin and etoposide had only modest synergistic effects. HU and cytarabine effectively enhanced nitroblue tetrazolium-reducing activity induced by 1,25(OH)2D3. HU also enhanced the morphol. maturation and expression of CD11b and CD14 in cells treated with 1,25(OH)2D3. Among the anticancer drugs examd., HU had the greatest synergistic effects with 1,25(OH)2D3 with regard to growth inhibition and differentiation induction in U937 cells. HU also enhanced the differentiation of other myeloid leukemia HL-60, ML-1, THP-1, P39/TSU, P31/FUJ and NB4 cells induced by 1,25(OH)2D3 and that of U937 cells induced by 24-epi-1,25(OH)2D2 and 1,25(OH)2D7. Interestingly, 1α(OH)D derivs. (1α-hydroxyvitamin D3, D2, D4 and D7) effectively induced the differentiation of monoblastic leukemia U937, P39/TSU and P31/FUJ cells. HU also enhanced the growth inhibition and differentiation of U937 cells induced by 1α(OH)D derivs. As 1α(OH)D derivs. preferentially act on monocytic cells, they may be useful in the treatment of acute monocytic leukemia, both alone and in combination with HU.